Literature DB >> 17916102

Clinical differences between children and adults with pulmonary hypertension and sickle cell disease.

R Ward Hagar1, Jennifer G Michlitsch, Jennifer Gardner, Elliott P Vichinsky, Claudia R Morris.   

Abstract

Pulmonary hypertension (PHT) is an important co-morbidity in sickle cell disease (SCD). Despite increasing research in adults, the prevalence and implication of this condition in children is unknown. Charts of 362 SCD patients followed at the Children's Hospital & Research Center Oakland were reviewed to determine clinical variables associated with obtaining echocardiographic screening for PHT, clinical associations of PHT, and associated mortality following diagnosis in adults and children with SCD. In this cohort, patients with underlying lung abnormalities or those on chronic transfusions were more likely to have echocardiograms, however the diagnosis of PHT was often unrecognized. A different clinical phenotype for PHT in adults versus children was identified. Associations with PHT for adults included age, renal and lung disease, hepatitis C, chronic transfusions, and a history of acute chest syndrome (ACS), with ACS being protective. Surprisingly, for children, a history of sepsis, along with a history of ACS, or obstructive lung disease were associated with PHT. Survival analysis found significant mortality for PHT, with a hazard ratio of 17.3 (95% confidence interval 4.9-60.4). The divergent clinical spectrum for PHT between adults and children may point to different age-specific mechanisms or biological expression of PHT.

Entities:  

Mesh:

Year:  2007        PMID: 17916102     DOI: 10.1111/j.1365-2141.2007.06822.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  22 in total

1.  Vascular risk assessment in patients with sickle cell disease.

Authors:  Claudia R Morris
Journal:  Haematologica       Date:  2011-01       Impact factor: 9.941

Review 2.  Pulmonary hypertension associated with sickle cell disease: pathophysiology and rationale for treatment.

Authors:  Raymond L Benza
Journal:  Lung       Date:  2008-05-10       Impact factor: 2.584

Review 3.  Minireview: Clinical severity in sickle cell disease: the challenges of definition and prognostication.

Authors:  Charles T Quinn
Journal:  Exp Biol Med (Maywood)       Date:  2016-03-23

4.  Longitudinal effect of disease-modifying therapy on tricuspid regurgitant velocity in children with sickle cell anemia.

Authors:  Parul Rai; Vijaya M Joshi; Jason F Goldberg; Amber M Yates; Victoria I Okhomina; Rhiannon Penkert; Kenneth I Ataga; Guolian Kang; Jane S Hankins
Journal:  Blood Adv       Date:  2021-01-12

5.  Cardiopulmonary complications leading to premature deaths in adult patients with sickle cell disease.

Authors:  Courtney D Fitzhugh; Naudia Lauder; Jude C Jonassaint; Marilyn J Telen; Xiongce Zhao; Elizabeth C Wright; Francis R Gilliam; Laura M De Castro
Journal:  Am J Hematol       Date:  2010-01       Impact factor: 10.047

6.  Left ventricular hypertrophy and diastolic dysfunction in children with sickle cell disease are related to asleep and waking oxygen desaturation.

Authors:  Mark C Johnson; Fenella J Kirkham; Susan Redline; Carol L Rosen; Yan Yan; Irene Roberts; Jeanine Gruenwald; Jan Marek; Michael R DeBaun
Journal:  Blood       Date:  2010-04-08       Impact factor: 22.113

7.  Elevated tricuspid regurgitation velocity and decline in exercise capacity over 22 months of follow up in children and adolescents with sickle cell anemia.

Authors:  Victor R Gordeuk; Caterina P Minniti; Mehdi Nouraie; Andrew D Campbell; Sohail R Rana; Lori Luchtman-Jones; Craig Sable; Niti Dham; Gregory Ensing; Josef T Prchal; Gregory J Kato; Mark T Gladwin; Oswaldo L Castro
Journal:  Haematologica       Date:  2010-09-30       Impact factor: 9.941

Review 8.  Pleiotropic effects of intravascular haemolysis on vascular homeostasis.

Authors:  Gregory J Kato; James G Taylor
Journal:  Br J Haematol       Date:  2009-12-01       Impact factor: 6.998

9.  Vasculopathy in sickle cell disease: Biology, pathophysiology, genetics, translational medicine, and new research directions.

Authors:  Gregory J Kato; Robert P Hebbel; Martin H Steinberg; Mark T Gladwin
Journal:  Am J Hematol       Date:  2009-09       Impact factor: 10.047

10.  Symptomatic pulmonary hypertension in a child with sickle cell disease.

Authors:  Karrie Villavicencio; Dunbar Ivy; Laura Cole; Rachelle Nuss
Journal:  J Pediatr       Date:  2008-06       Impact factor: 4.406

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.